Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of ...

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 ...

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS ...
PharmiWeb

3D Bioprinting Market To High Growth Opportunities, Emerging Trends, Market Review, Global Forecast 2029

Global 3D Bioprinting Market OverviewThe global 3D bioprinting market is poised for strong growth, with projections indicating a compound annual growth rate of 12–15% over the next five years. This ...

Vagus Nerve Stimulation Market is expected to generate a revenue of USD 23.73 Billion by 2031, Globally, at 10.50% CAGR: Verified Market Research®

The Global Vagus Nerve Stimulation Market Size projected to grow at a CAGR of 10.50% from 2024 to 2031, according to a new ...
Le Lézard

Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment ...

DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...

Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative …

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...
Le Lézard

BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a ...

BioInvent International: BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a favorab ...

ProstaVive Circulation Support Investigation: What 2026 Consumer Data Shows About Nitric Oxide Prostate Supplements

Nitric Oxide Support Analysis Examines Boron, Tongkat Ali, Fenugreek, Panax Ginseng, and Vitamin D3 Formulation Amid January ...

AI uncovers two distinct multiple sclerosis types

Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been ...

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Disea…

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 ...
Frontiers

Balancing innovation and safety in percutaneous treatment of coronary artery calcification

Coronary artery disease characterized by vascular calcification poses significant challenges in the field of interventional ...